TY - JOUR
T1 - ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
AU - ARAS investigators
AU - Farhang, Sara
AU - Shirzadi, Maryam
AU - Alikhani, Rosa
AU - Amiri, Shahrokh
AU - Mohagheghi, Arash
AU - Naghdi-sadeh, Reza
AU - Malek, Ayyoub
AU - Shafiei-kandjani, Alireza
AU - Ranjbar, Fatemeh
AU - Fakhari, Ali
AU - Noorazar, Gholamreza
AU - Herizchi, Sepideh
AU - Adalatzadeh, Golnaz
AU - Naderi, Anis
AU - Alizadeh, Behrooz Z.
AU - Bruggeman, Richard
AU - Veling, Wim
N1 - Funding Information:
This prospective cohort of the first episode psychosis (FEP) was designed by a steering committee from Department of Psychiatry, Tabriz University of Medical Sciences, Iran and Departments of Psychiatry and Epidemiology, University Medical Center Groningen, the Netherlands. The study protocol which is described in a published paper, was approved by the Iranian national ethical committee (IR.NIMAD.REC.1396.101), and is funded by Iranian National Institute for research in medical sciences.
Funding Information:
Authors would like to thank clinical research development units of Razi hospital. This study was funded by the National Institute for Medical Research Development (NIMAD), Iran.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context. Here, baseline characteristics of the ARAS cohort are reported. The ARAS cohort enrolled patients with recent onset psychosis from September 2018 to September 2021 in East Azerbaijan, Kermanshah and Tehran, including Iranian patients from different sociocultural contexts. The baseline assessment included demographics, socioeconomic status, clinical (positive, negative, depressive symptoms) and psychosocial (religiosity, social support, self-stigma) characteristics, cognitive functioning, metabolic profile, substance use and medication use measured by validated questionnaires. These assessments will be followed up after one and five years. A total of 500 patients with a first episode of psychosis were enrolled from three provinces in Iran. With 74.1% being male, the mean age (SD) of patients was 32.3 (9.7) years. Nearly a quarter of patients was diagnosed with schizophrenia and 36.8% with substance induced psychotic disorder. Amphetamine (24%) and opium (12%) use were common, cannabis use was not (5%). Only 6.1% of patients lived alone while 29% of patients was married and had children. The majority of them had achieved secondary educational level and 34% had a paid job. The most common antipsychotic treatment was risperidone. There was a wide range for scores of PANSS, with 9.4% having dominant negative symptoms. The most common prescribed medication was risperidone. Near to 40% of patients had noticeable signs of depression and prevalence of metabolic syndrome was 13.4%. The majority of patients (57.2%) had moderate and 5.4% reported to have severe disability. More than 30% reported to be highly religious. Patients had the highest satisfaction with people living with, and the lowest for finance and job.
AB - The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context. Here, baseline characteristics of the ARAS cohort are reported. The ARAS cohort enrolled patients with recent onset psychosis from September 2018 to September 2021 in East Azerbaijan, Kermanshah and Tehran, including Iranian patients from different sociocultural contexts. The baseline assessment included demographics, socioeconomic status, clinical (positive, negative, depressive symptoms) and psychosocial (religiosity, social support, self-stigma) characteristics, cognitive functioning, metabolic profile, substance use and medication use measured by validated questionnaires. These assessments will be followed up after one and five years. A total of 500 patients with a first episode of psychosis were enrolled from three provinces in Iran. With 74.1% being male, the mean age (SD) of patients was 32.3 (9.7) years. Nearly a quarter of patients was diagnosed with schizophrenia and 36.8% with substance induced psychotic disorder. Amphetamine (24%) and opium (12%) use were common, cannabis use was not (5%). Only 6.1% of patients lived alone while 29% of patients was married and had children. The majority of them had achieved secondary educational level and 34% had a paid job. The most common antipsychotic treatment was risperidone. There was a wide range for scores of PANSS, with 9.4% having dominant negative symptoms. The most common prescribed medication was risperidone. Near to 40% of patients had noticeable signs of depression and prevalence of metabolic syndrome was 13.4%. The majority of patients (57.2%) had moderate and 5.4% reported to have severe disability. More than 30% reported to be highly religious. Patients had the highest satisfaction with people living with, and the lowest for finance and job.
U2 - 10.1038/s41537-022-00295-z
DO - 10.1038/s41537-022-00295-z
M3 - Article
AN - SCOPUS:85142289027
SN - 2334-265X
VL - 8
JO - Schizophrenia
JF - Schizophrenia
M1 - 101
ER -